Integra LifeSciences Holdings Corporation (NASDAQ: IART) and Sientra (NASDAQ:SIEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Integra LifeSciences Holdings Corporation and Sientra, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences Holdings Corporation 0 2 8 0 2.80
Sientra 0 0 4 0 3.00

Integra LifeSciences Holdings Corporation presently has a consensus price target of $53.45, suggesting a potential upside of 2.95%. Sientra has a consensus price target of $13.67, suggesting a potential downside of 11.49%. Given Integra LifeSciences Holdings Corporation’s higher probable upside, equities research analysts plainly believe Integra LifeSciences Holdings Corporation is more favorable than Sientra.

Earnings & Valuation

This table compares Integra LifeSciences Holdings Corporation and Sientra’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Integra LifeSciences Holdings Corporation $1.05 billion 3.86 $240.98 million $0.82 63.32
Sientra $28.68 million 10.39 -$35.42 million ($2.66) -5.80

Integra LifeSciences Holdings Corporation has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Integra LifeSciences Holdings Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integra LifeSciences Holdings Corporation and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra LifeSciences Holdings Corporation 6.27% 16.79% 7.35%
Sientra -173.83% -52.30% -37.51%

Volatility & Risk

Integra LifeSciences Holdings Corporation has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Sientra has a beta of -1.57, indicating that its stock price is 257% less volatile than the S&P 500.

Insider & Institutional Ownership

85.3% of Integra LifeSciences Holdings Corporation shares are held by institutional investors. Comparatively, 77.6% of Sientra shares are held by institutional investors. 21.5% of Integra LifeSciences Holdings Corporation shares are held by insiders. Comparatively, 28.1% of Sientra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Integra LifeSciences Holdings Corporation beats Sientra on 10 of the 13 factors compared between the two stocks.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

About Sientra

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.